<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335052">
  <stage>Registered</stage>
  <submitdate>20/01/2010</submitdate>
  <approvaldate>21/01/2010</approvaldate>
  <actrnumber>ACTRN12610000077066</actrnumber>
  <trial_identification>
    <studytitle>Does Suppression of Atrial Fibrillation (AF) Promote Reverse Electrical Remodeling of the Atria?</studytitle>
    <scientifictitle>Prospective, Randomized, Follow up Study of the St. Jude Medical identity AFx DR to determine whether or not the reduction of Atrial Fibrillation (AF) by the AF suppression algorithm halts or reverses electrical remodeling that has already begun in AF patients</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>SAFER PACE</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study aims at determining whether or not the reduction of Atrial Fibrillation (AF) by the AF suppression algorithm halts or reverses electrical remodeling that has already begun in AF patients. The algorithm provides stimulation that controls the atrial rate and rhythm minimising ectopic beats, long-short cycles and dispersion of refractoriness. It does this by monitoring the intrinsic atrial rhythm and then adapting the pacing rate slightly above the intrinsic rhythm to help ensure a high percentage of atrial pacing that is dynamically tailored to the patients rate variations. From the point of implant the device is constantly monitoring and correcting the pacing of the heart. The duration of the study is 6 months, the device will remain implanted and continue to treat the patient: Changing of the status of the AF supression algorithm being 'ON' or 'OFF' is at the discretion of the physician.</interventions>
    <comparator>The control group will have their device's Atrial Fibrillation Suppression Algorithm switched 'OFF' for the entire follow up period. This will be a constant feature from the point of implant. The duration of the study is 6 months, the device will remain implated at the end of the study: Changing of the status of the AF suppression algorithm being 'ON' or 'OFF' is at the discretion of the physician.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Atrial Effectice Refractory Period (AERP) assessed using Non-invasive programmed stimulation (NIPS) via device interrogation</outcome>
      <timepoint>measured at implant, 3 and 6 month follow up visits</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Atrial Fibrillation (AF) Burdon: Total duration of AF episodes/follow up. This will be assessed through Device Interrogation</outcome>
      <timepoint>All Follow up visits (3 and 6 month post implant)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AF Frequency: Number of AF episodes/time in sinus Rhythm. This will also be assessed through device interrogation</outcome>
      <timepoint>All Follow up Visits (3 and 6 months post implant)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Auto Mode Switch (AMS) Occurances assessed through device interrogation</outcome>
      <timepoint>All Follow up visits (3 and 6 months post implant)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AMS duration assessed through device interrogation</outcome>
      <timepoint>All Follow up visits (3 and 6 months post implant)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Patient must have standard indications for a DDD (Dual Chamber) pacemaker
- Patient must have documented paroxysmal or persistent Atrial Fibrillation (AF).
- Patient must be maintained on a stable antiarrhythmic drug regimen</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Patient has chronic Atrial Fibrillation
- Patient has Class 3 or 4 angina
- Patient has an existing Implantable Cardioverter Defibrillator (ICD) or is being considered for an ICD implant.
- Patients life expectancy is less than 6 months due to other medical conditions
- Patient has a serious comorbid condition (i.e. metastaic disease, chronic renal failure etc)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>At implant each patient will be randomised to AF Suppression 'ON' or 'OFF', allocation concealment will be the method by which patients will be designated to their treatment group. Allocation will be through  an off site contact with the randomisation procedures/schedule.</concealment>
    <sequence>Randomisation allocation is according to age: greater or less than 75 then by simple randomisation using alternate alotment</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate>29/06/2005</actualstartdate>
    <anticipatedenddate>12/10/2009</anticipatedenddate>
    <actualenddate>12/10/2009</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize>61</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <postcode>6001</postcode>
    <postcode>3084</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress>St. Jude Medical Australia
17 Orion Rd
Lane Cove NSW 2066</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St. Jude Medical</fundingname>
      <fundingaddress>St. Jude Medical Australia
17 Orion Rd
Lane Cove NSW 2066</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether or not the reduction of Atrial Fibrillation (AF) by the AF Suppression algorithm halts or reverses the electrical remodeling that has already begun in AF Patients</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South B. Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of health 
4th Floor, 250 Oxford Tce
PO Box 3877 CHRISTCHURCH NZ</ethicaddress>
      <ethicapprovaldate>2/05/2005</ethicapprovaldate>
      <hrec>URB/05/02/013</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Kirkman House 
Wellington Street Campus
GPO Box X2213 
PERTH WA 6847</ethicaddress>
      <ethicapprovaldate>9/08/2005</ethicapprovaldate>
      <hrec>20005/072</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Heidelberg Repatriation Hospital
300 Waterdale Rd
Heidelberg West VIC 3081</ethicaddress>
      <ethicapprovaldate>20/06/2005</ethicapprovaldate>
      <hrec>H2005/02181</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Jessica Andrews</name>
      <address>St. Jude Medical Australia
17 Orion Rd
Lane Cove NSW 2066</address>
      <phone>+612 9936 1236</phone>
      <fax>+612 9936 1222</fax>
      <email>jandrews04@sjm.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Jessica Andrews</name>
      <address>St. Jude Medical Australia
17 Orion Rd 
Lane Cove NSW 2066</address>
      <phone>+612 9936 1236</phone>
      <fax>+612 9936 1222</fax>
      <email>jandrews04@sjm.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jessica Andrews</name>
      <address>St. Jude Medical Australia
17 Orion Rd
Lane Cove NSW 2066</address>
      <phone>+612 9936 1236</phone>
      <fax>+612 9936 1222</fax>
      <email>jandrews04@sjm.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Ian Crozier</name>
      <address>Christchurch Hosptial
Riccarton Avenue
Christchurch 8140
NEW ZEALAND

</address>
      <phone>+64 3 3640 640</phone>
      <fax />
      <email>Ian.Crozier@cdhb.govt.nz </email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>